Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus UNIPEN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus UNIPEN IN PLASTIC CONTAINER.
AMPICILLIN AND SULBACTAM vs UNIPEN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity. Sulbactam is a β-lactamase inhibitor that irreversibly inhibits a broad range of β-lactamases, preventing degradation of ampicillin.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and peptidoglycan cross-linking.
1.5-3 g (ampicillin 1-2 g + sulbactam 0.5-1 g) IV/IM every 6 hours. Maximum daily dose of sulbactam is 4 g.
250-500 mg intravenously or intramuscularly every 4-6 hours. Maximum dose 12 g per day.
None Documented
None Documented
Ampicillin: 1-1.8 hours; sulbactam: 1-1.5 hours. Prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: up to 8-12 hours).
0.5-1 hour (normal renal function); prolonged to 2-5 hours in renal impairment
Primarily renal (70-75% unchanged ampicillin, 75-80% unchanged sulbactam). Biliary excretion accounts for ~25% of ampicillin and ~20% of sulbactam. Fecal elimination is minor (<5%).
Renal: 60-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: minor, <10%
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic